ImmunoPrecise Antibodies Ltd. (HYFT) — Strategic Asset Allocation Index
ImmunoPrecise Antibodies Ltd. (HYFT) has a Strategic Asset Allocation Index of 0.0% as of April 2024. Strategic assets (PP&E of $- plus long-term investments of $0.00) total $0.00, measured against net assets of $33.92 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
ImmunoPrecise Antibodies Ltd. Strategic Asset Allocation Index (2022–2024)
This chart shows how ImmunoPrecise Antibodies Ltd.'s Strategic Asset Allocation Index has evolved across 3 annual periods from 2022 to 2024. As of April 2024, the index stands at 0.0%, representing strategic assets of $0.00 against net assets of $33.92 Million USD. Explore ImmunoPrecise Antibodies Ltd. (HYFT) cash flow conversion to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for ImmunoPrecise Antibodies Ltd. (2022–2024)
The table below presents the year-by-year Strategic Asset Allocation Index for ImmunoPrecise Antibodies Ltd. from 2022 to 2024, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see HYFT market cap.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 0.0% | $0.00 | $- | $0.00 | $33.92 Million | ▼ -0.2 pp |
| 2023 | 0.2% | $115.00K | $- | $115.00K | $57.80 Million | ▲ +0.0 pp |
| 2022 | 0.2% | $142.00K | $- | $142.00K | $75.13 Million | — |